199 related articles for article (PubMed ID: 30704939)
1. Possible contribution of PDGF-BB-induced autophagy in dermatofibrosarcoma protuberans: Autophagy marker Atg5 could be a differential marker between dermatofibrosarcoma protuberans and dermatofibroma.
Motegi SI; Fujiwara C; Sekiguchi A; Yamazaki S; Yokoyama Y; Yasuda M; Ishikawa O
J Dermatol Sci; 2019 Feb; 93(2):139-141. PubMed ID: 30704939
[No Abstract] [Full Text] [Related]
2. Giant cell fibroblastoma in a child misdiagnosed as a dermatofibroma.
Nguyen CM; Burch JM; Fitzpatrick JE; Peterson SL; Weston WL
Pediatr Dermatol; 2002; 19(1):28-32. PubMed ID: 11860566
[TBL] [Abstract][Full Text] [Related]
3. High proliferative activity excludes dermatofibroma: report of the utility of MIB-1 in the differential diagnosis of selected fibrohistiocytic tumors.
Hanly AJ; Jordà M; Elgart GW; Badiavas E; Nassiri M; Nadji M
Arch Pathol Lab Med; 2006 Jun; 130(6):831-4. PubMed ID: 16740036
[TBL] [Abstract][Full Text] [Related]
4. When Immunohistochemistry Deceives Us: The Pitfalls of CD34 and Factor XIIIa Stains in Dermatofibroma and Dermatofibrosarcoma Protuberans.
John AM; Holahan HH; Singh P; Handler MZ; Lambert WC
Skinmed; 2017; 15(1):53-55. PubMed ID: 28270311
[No Abstract] [Full Text] [Related]
5. Atrophic variants of dermatofibroma and dermatofibrosarcoma protuberans.
Zelger BW; Ofner D; Zelger BG
Histopathology; 1995 Jun; 26(6):519-27. PubMed ID: 7545142
[TBL] [Abstract][Full Text] [Related]
6. Expression of CD163 in dermatofibroma, cellular fibrous histiocytoma, and dermatofibrosarcoma protuberans: comparison with CD68, CD34, and Factor XIIIa.
Sachdev R; Sundram U
J Cutan Pathol; 2006 May; 33(5):353-60. PubMed ID: 16640542
[TBL] [Abstract][Full Text] [Related]
7. Apolipoprotein D in CD34-positive and CD34-negative cutaneous neoplasms: a useful marker in differentiating superficial acral fibromyxoma from dermatofibrosarcoma protuberans.
Lisovsky M; Hoang MP; Dresser KA; Kapur P; Bhawan J; Mahalingam M
Mod Pathol; 2008 Jan; 21(1):31-8. PubMed ID: 17885669
[TBL] [Abstract][Full Text] [Related]
8. CD34-positive myxoid dermatofibrohistiocytoma of the skin: an indolent post-traumatic tumor that can be mistaken for dermatofibrosarcoma protuberans.
Al-Quran SZ; Russo JJ; Bandarchi-Chamkhaleh B; Hassanein AM
J Cutan Pathol; 2009 Jan; 36(1):84-6. PubMed ID: 19125740
[No Abstract] [Full Text] [Related]
9. Stromelysin 3 expression: a useful marker for the differential diagnosis dermatofibroma versus dermatofibrosarcoma protuberans.
Cribier B; Noacco G; Peltre B; Grosshans E
J Am Acad Dermatol; 2002 Mar; 46(3):408-13. PubMed ID: 11862177
[TBL] [Abstract][Full Text] [Related]
10. D2-40, a novel immunohistochemical marker in differentiating dermatofibroma from dermatofibrosarcoma protuberans.
Bandarchi B; Ma L; Marginean C; Hafezi S; Zubovits J; Rasty G
Mod Pathol; 2010 Mar; 23(3):434-8. PubMed ID: 20062007
[TBL] [Abstract][Full Text] [Related]
11. The pathological distinction between "deep penetrating" dermatofibroma and dermatofibrosarcoma protuberans.
Wick MR; Ritter JH; Lind AC; Swanson PE
Semin Cutan Med Surg; 1999 Mar; 18(1):91-8. PubMed ID: 10188848
[TBL] [Abstract][Full Text] [Related]
12. CD34 and factor-XIIIa immunoreactivity in dermatofibrosarcoma protuberans and dermatofibroma.
Goldblum JR; Tuthill RJ
Am J Dermatopathol; 1997 Apr; 19(2):147-53. PubMed ID: 9129699
[TBL] [Abstract][Full Text] [Related]
13. Dermatofibroma and dermatofibrosarcoma protuberans: differential expression of CD34 and factor XIIIa.
Cohen PR; Rapin RP; Farhood AI
Am J Dermatopathol; 1994 Oct; 16(5):573-4. PubMed ID: 7528477
[No Abstract] [Full Text] [Related]
14. Sclerosing Dermatofibrosarcoma Protuberans Shows Significant Overlap With Sclerotic Fibroma in Both Routine and Immunohistochemical Analysis: A Potential Diagnostic Pitfall.
Abdaljaleel MY; North JP
Am J Dermatopathol; 2017 Feb; 39(2):83-88. PubMed ID: 28134725
[TBL] [Abstract][Full Text] [Related]
15. Differential expression of HMGA1 and HMGA2 in dermatofibroma and dermatofibrosarcoma protuberans: potential diagnostic applications, and comparison with histologic findings, CD34, and factor XIIIa immunoreactivity.
Li N; McNiff J; Hui P; Manfioletti G; Tallini G
Am J Dermatopathol; 2004 Aug; 26(4):267-72. PubMed ID: 15249855
[TBL] [Abstract][Full Text] [Related]
16. Atrophic dermatofibroma accompanied by aneurysmatic characteristics.
Curcó N; Pagerols X; García M; Tarroch X; Vives P
J Eur Acad Dermatol Venereol; 2006 Mar; 20(3):331-3. PubMed ID: 16503899
[TBL] [Abstract][Full Text] [Related]
17. Fat necrosis with an associated lymphocytic infiltrate represents a histopathologic clue that distinguishes cellular dermatofibroma from dermatofibrosarcoma protuberans.
Schechter SA; Bresler SC; Patel RM
J Cutan Pathol; 2020 Oct; 47(10):913-916. PubMed ID: 32412128
[TBL] [Abstract][Full Text] [Related]
18. LN-2 (CD74). A marker to distinguish atypical fibroxanthoma from malignant fibrous histiocytoma.
Lazova R; Moynes R; May D; Scott G
Cancer; 1997 Jun; 79(11):2115-24. PubMed ID: 9179057
[TBL] [Abstract][Full Text] [Related]
19. Recent advances in the diagnosis, classification and molecular pathogenesis of cutaneous mesenchymal neoplasms.
Papke DJ; Hornick JL
Histopathology; 2022 Jan; 80(1):216-232. PubMed ID: 34958499
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical characterization of dermatofibrosarcoma protuberans with practical applications for diagnosis and treatment.
Haycox CL; Odland PB; Olbricht SM; Piepkorn M
J Am Acad Dermatol; 1997 Sep; 37(3 Pt 1):438-44. PubMed ID: 9308560
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
